While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.
Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...
As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural ...
Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...
13don MSN
While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...
Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...
US vaccines developer Moderna today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine ...
Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years. "This agreement presents an opportunity for Moderna to support and ...
"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback